In December 2023, a new study reported that in patients who had cardiovascular disease and obesity, but not diabetes, semaglutide was able to reduce the risk of heart attack, stroke, or death by 20%
Ning M-M, Yang W-J, Guan W-B, Gu Y-P, Feng Y, Leng Y
Filingeri noted that this research study was designed to further examine changes in weight, body fat mass, and muscle mass in patients taking incretin medications. We found that, under close supervision and regular follow-up from an obesity medicine specialist, patients were able to lose fat mass with only a minimal decline in muscle mass. Alexandra Filingeri, DCN, RCN Filingeri pointed out that the results of this study cannot be generalized to patients receiving medication via telemedicine without routine body composition analysis, nor can they be generalized to in-person visits without utilizing body composition analysis
Rijal, K
Could significantly reduce injection burden vs weekly dosing